Skip to main content
. 2020 Feb 24;20:152. doi: 10.1186/s12885-020-6660-7

Table 3.

Multivariate analysis of various factors correlated with progression-free survival

No. of patients PFS
Multivariate analysis
HR (95% CI) P
Age, years (continuous) 168 1.025 (0.956–1.099) 0.4894
LC
 2006~2012 77 1 (Reference)
 2013~2018 91 0.065 (0.007–0.603) 0.0162*
BMI
 < 25 130 1 (Reference)
 ≥ 25 38 0.243 (0.025–2.404) 0.2264
Stage
 IB1, IB2 141 1 (Reference)
 IA1, IA2 27 0.638 (0.092–4.446) 0.6502
Histology
 SCC 118 1 (Reference)
 AC & AS 50 1.367 (0.375–4.986) 0.6357
Invasiveness
 < 0.3 cm 97 1 (Reference)
 ≥ 0.3 cm 71 1.139 (0.297–4.363) 0.8493
LVSI
 No 128 1 (Reference)
 Yes 40 4.590 (0.973–21.659) 0.0543
No. of harvested LNs
 < 20 129 1 (Reference)
 ≥ 20 39 0.325 (0.068–1.557) 0.1597
Metastatic LNs
 No 155 1 (Reference)
 Yes 13 2.609 (0.424–16.041) 0.3006
Tumor size
 < 2 cm 125 1 (Reference)
 ≥ 2 cm 43 5.651 (1.255–25.448) 0.0241*
Postoperative treatment
 Yes 34 1 (Reference) 0.0755
 No 134 0.185 (0.029–1.189)

PFS Progression-free survival, HR Hazard ratio, CI Confidential interval, LC Learning curve, BMI Body mass index, SCC Squamous cell carcinoma, AC Adenocarcinoma, AS Adenosquamous, LVSI Lymphovascular space invasion, LN Lymph node; *, P < 0.05